{"id":10577,"date":"2026-01-21T06:27:34","date_gmt":"2026-01-21T00:57:34","guid":{"rendered":"https:\/\/indianpharmanetwork.co.in\/medicines\/?post_type=product&p=10577"},"modified":"2026-05-19T19:38:06","modified_gmt":"2026-05-19T14:08:06","slug":"imdelltra-tarlatamab-dlle","status":"publish","type":"product","link":"https:\/\/indianpharmanetwork.co.in\/medicines\/product\/imdelltra-tarlatamab-dlle\/","title":{"rendered":"IMDELLTRA (tarlatamab-dlle) for injection"},"content":{"rendered":"

Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer.<\/strong> It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3. The most common adverse reactions include cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea.<\/p>\n

The drug, tarlatamab, is now approved to treat adults whose extensive-stage small cell lung cancer has progressed on or after treatment with platinum-based chemotherapy.<\/p>\n

Small cell lung cancer (SCLC) is less common than non-small cell lung cancer, but it is more aggressive, rapidly spreading to other parts of the body. The five-year survival rate for extensive-stage SCLC is 3%,\u00a0according to the American Cancer Society. Second-line treatments for this advanced cancer include more chemotherapy as well as a class of immunotherapies called checkpoint inhibitors, which block proteins that cancers use to evade detection by the immune system.<\/p>\n

IMDELLTRA\u2122 (tarlatamab-dlle) for injection, for intravenous use Initial U.S. Approval: 2024 <\/strong><\/p>\n

Is IMDELLTRA (tarlatamab-dlle) available in India?<\/h4>\n

IMDELLTRA (tarlatamab-dlle) may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n

How to get IMDELLTRA injection delivered in India?<\/h4>\n

Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n

IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n

Who can help source IMDELLTRA injection in India legally?<\/h4>\n

Named-patient import facilitator contact details<\/strong>
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n

Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n

NEWS\/UPDATES<\/p>\n